Drug Profile
BMS 181170
Alternative Names: BMS-181170; BMY 35037Latest Information Update: 18 Jan 2008
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Anti-infectives; Monoclonal antibodies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Septic shock
Most Recent Events
- 14 Jul 1998 No-Development-Reported for Septic shock in USA (Unknown route)
- 04 May 1995 Preclinical development for Septic shock in USA (Unknown route)